Study of TRX-100 Evaluating the Safety, Pharmacokinetics, and Food Effect in Healthy Volunteers

← catalyst calendar

NCT07526506 · readout ≤ 42 d

Sponsored by Traws Pharma, Inc. (industry) · TRAW — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Randomized · Double · Treatment

Enrollment

32estimated

Sites

Country

Australia

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-03-25

actual

When the study began enrolling

Primary completion

Sep 2026

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Feb 2027

estimated

The whole study's end, after follow-up

First posted

2026-04-13

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-03

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Healthy Volunteer

Interventions

Drug: TRX-100
Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Incidence, severity, and relationship of treatment-emergent adverse events

measured From administration of study drug on Day 1 through the end-of-study visit on Day 28 (±2 days).

Incidence of serious adverse events and adverse events leading to discontinuation

measured From administration of study drug on Day 1 through the end-of-study visit on Day 28 (±2 days).

Permalink · TRAW's whole pipeline · Catalyst calendar · Every registered study · What changed